Who is the CEO of Paion AG?

Mr. Tilmann Bur is a business executive who currently serves as the CEO of Paion AG.

What is the Revenue Growth of Paion AG?

Revenue growth data for Paion AG is currently unavailable.

What is Paion AG operating Margin?

Paion AG operating margin is 7.83% which shows how much profit PA8.DE earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Paion AG operate?

Paion AG falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Paion AG revenue growth?

Revenue growth data for Paion AG is currently unavailable.

Paion AG

PA8.DE•XETRA

HealthcareDrug Manufacturers - Specialty & Generic

$0.36

$0.01(4.35%)

Paion AG (PA8.DE) Stock Overview

Explore Paion AG’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for PA8.DEStats details for PA8.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for PA8.DEAnalyst Recommendations details for PA8.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.

CEO

Mr. Tilmann Bur

Employees

Headquarters

Heussstrasse 25, Aachen

Founded

2022